Year |
Citation |
Score |
2023 |
Stephenson KG, Lingle AJ, Baumberger KA, Dellon EP, Esther CR, Meier EM, Oermann CM, Shenoy VK, Smith NR, Wimmer NS, Duehlmeyer SR, Kam CW, McKinzie CJ, Poisson MO, Elson EC. Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 37758535 DOI: 10.1016/j.jcf.2023.09.005 |
0.363 |
|
2020 |
Elson EC, Meier E, Oermann CM. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32811788 DOI: 10.1016/j.jcf.2020.08.002 |
0.44 |
|
2019 |
Elson EC, Mermis J, Polineni D, Oermann CM. Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine. 13: 1179548419842822. PMID 31019373 DOI: 10.1177/1179548419842822 |
0.418 |
|
2018 |
Ren CL, Morgan RL, Oermann C, Resnick HE, Brady C, Campbell A, DeNagel R, Guill M, Hoag J, Lipton A, Newton T, Peters S, Willey-Courand DB, Naureckas ET. Cystic Fibrosis Pulmonary Guidelines: Use of CFTR Modulator Therapy in Patients with Cystic Fibrosis. Annals of the American Thoracic Society. PMID 29342367 DOI: 10.1513/AnnalsATS.201707-539OT |
0.41 |
|
2015 |
Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 111-9. PMID 25091537 DOI: 10.1016/J.Jcf.2014.06.003 |
0.487 |
|
2015 |
Tiddens H, De Boeck K, Clancy J, Fayon M, Arets H, Bresnik M, Derchak P, Lewis S, Oermann C. WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use Journal of Cystic Fibrosis. 14: S3. DOI: 10.1016/S1569-1993(15)30008-4 |
0.345 |
|
2014 |
Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM, Ratjen F, Rosenfeld M, Simon RH, Hazle L, Sabadosa K, Marshall BC, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Annals of the American Thoracic Society. 11: 1640-50. PMID 25549030 DOI: 10.1513/Annalsats.201404-166Oc |
0.478 |
|
2013 |
Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 12: 130-40. PMID 22985692 DOI: 10.1016/j.jcf.2012.07.006 |
0.332 |
|
2011 |
Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). The Journal of Antimicrobial Chemotherapy. 66: 2398-404. PMID 21784781 DOI: 10.1093/Jac/Dkr303 |
0.391 |
|
2011 |
Pressler T, Assael B, Fischer R, Bresnik M, Lewis S, McKevitt M, Montgomery A, Oermann C. 107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75 mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis (CF) Journal of Cystic Fibrosis. 10: S27. DOI: 10.1016/S1569-1993(11)60124-0 |
0.326 |
|
2010 |
Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology. 45: 1121-34. PMID 20672296 DOI: 10.1002/Ppul.21301 |
0.447 |
|
2009 |
Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 135: 1223-32. PMID 19420195 DOI: 10.1378/Chest.08-1421 |
0.481 |
|
2009 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Adherence over multiple courses of Aztreonam Lysine for Inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60113-2 |
0.482 |
|
2009 |
McCoy K, Retsch-Bogart G, Gibson R, Oermann C, McKevitt M, Montgomery A. Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60112-0 |
0.345 |
|
2009 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Montgomery A. Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006 Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60111-9 |
0.449 |
|
2008 |
McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 178: 921-8. PMID 18658109 DOI: 10.1164/Rccm.200712-1804Oc |
0.518 |
|
2008 |
Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology. 43: 47-58. PMID 18041081 DOI: 10.1002/Ppul.20736 |
0.484 |
|
2008 |
McCoy K, Retsch-Bogart G, Gibson R, Oermann C, Braff M, Montgomery A. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) Journal of Cystic Fibrosis. 7: S36. DOI: 10.1016/S1569-1993(08)60138-1 |
0.439 |
|
2008 |
Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data Journal of Cystic Fibrosis. 7: S25. DOI: 10.1016/S1569-1993(08)60097-1 |
0.47 |
|
2007 |
Garcia DF, Hiatt PW, Jewell A, Schoonover SL, Cron SG, Riggs M, Grace S, Oermann CM, Piedra PA. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatric Pulmonology. 42: 66-74. PMID 17123316 DOI: 10.1002/Ppul.20546 |
0.307 |
|
2007 |
McCoy K, Retsch-Bogart G, Oermann C, Gibson R, Montgomery A. 40* Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection Journal of Cystic Fibrosis. 6: S10. DOI: 10.1016/S1569-1993(07)60033-2 |
0.462 |
|
2006 |
Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology. 41: 656-65. PMID 16703579 DOI: 10.1002/Ppul.20429 |
0.546 |
|
2005 |
Oermann CM, Al-Salmi Q, Seilheimer DK, Finegold M, Tatevian N. Mucinous cystadenocarcinoma of the pancreas in an adolescent with cystic fibrosis. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 8: 391-6. PMID 16010483 DOI: 10.1007/S10024-005-4114-5 |
0.316 |
|
2001 |
Oermann CM. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Current Opinion in Investigational Drugs (London, England : 2000). 2: 900-6. PMID 11757788 |
0.323 |
|
2001 |
Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatric Pulmonology. 32: 372-7. PMID 11596162 DOI: 10.1002/Ppul.1146 |
0.317 |
|
2000 |
Oermann CM. Fertility in patients with cystic fibrosis. Chest. 118: 893-4. PMID 11035652 |
0.419 |
|
2000 |
Janahi IA, Maciejewski SR, Teran JM, Oermann CM. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatric Pulmonology. 30: 257-9. PMID 10973044 DOI: 10.1002/1099-0496(200009)30:3<257::Aid-Ppul10>3.0.Co;2-R |
0.346 |
|
2000 |
Oermann CM, Swank PR, Sockrider MM. Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis. Chest. 118: 92-7. PMID 10893365 DOI: 10.1378/Chest.118.1.92 |
0.303 |
|
1999 |
Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 115: 1053-8. PMID 10208207 DOI: 10.1378/Chest.115.4.1053 |
0.336 |
|
1999 |
Murry DJ, Kearns GL, Oermann C, Gaedigk A, Sockrider M, Seilheimer DK, Leeder JS. CYP2C9 genotype and ibuprofen (IBU) pharmacokinetics (PK) in cystic fibrosis (CF) Clinical Pharmacology and Therapeutics. 65: 140. DOI: 10.1016/S0009-9236(99)80092-7 |
0.444 |
|
1997 |
Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. The Pediatric Infectious Disease Journal. 16: 257-9. PMID 9041615 DOI: 10.1097/00006454-199702000-00021 |
0.417 |
|
Show low-probability matches. |